Monday, December 1, 2008

MedImmune Receives FDA Complete Response Letter on Motavizumab

Nov. 28, 2008-AstraZeneca today announced that MedImmune, its wholly owned biologics business, has received a Complete Response Letter (CRL) from the U.S. FDA asking for additional information on motavizumab.

The details can be read here.

No comments: